Randomised studies have shown that switching to a TAF-based regimen is generally safer than continuing to take TDF-containing regimens, particularly for bone and kidney health • How these trial results might have impacted on daily prescriptions in clinical practice is unknown and there is little data describing the population who have been switched to TAF-based regimens

Use of TAF with a HIV-RNA <50 cp/mL in clinical practice.

G. Nunnari;G. F. Pellicanò.
2018-01-01

Abstract

Randomised studies have shown that switching to a TAF-based regimen is generally safer than continuing to take TDF-containing regimens, particularly for bone and kidney health • How these trial results might have impacted on daily prescriptions in clinical practice is unknown and there is little data describing the population who have been switched to TAF-based regimens
2018
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3141690
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact